Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Scoring People With Spinal Muscular Atrophy on the Motor Function Measure Using the Microsoft Kinect

Journal article

Vincent-Genod D. et al, (2023), Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association, 35, 36 - 41

Early clinical and pre-clinical therapy development in Nemaline Myopathy.

Journal article

Fisher G. et al, (2022), Expert Opin Ther Targets

Growth pattern trajectories in boys with Duchenne muscular dystrophy

Journal article

Stimpson G. et al, (2022), Orphanet Journal of Rare Diseases, 17

The ethics of crowdfunding in paediatric neurology.

Journal article

Livingstone A. et al, (2022), Dev Med Child Neurol

Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.

Journal article

Le Goff L. et al, (2022), Neurol Sci

Emerging therapies for Duchenne muscular dystrophy.

Journal article

Markati T. et al, (2022), Lancet Neurol

Onasemnogene abeparvovec for the treatment of spinal muscular atrophy.

Journal article

McMillan HJ. et al, (2022), Expert Opin Biol Ther

Risdiplam: an investigational motor neuron-2 (SMN-2) splicing modifier for spinal muscular atrophy (SMA).

Journal article

Markati T. et al, (2022), Expert opinion on investigational drugs

Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen.

Journal article

Menard J. et al, (2022), Pediatric pulmonology

Load More